Psilocybin is still Schedule I federally — Compass Pathways says so in its own SEC filing, noting the drug "must be rescheduled before commercializing COMP360 psilocybin in the U.S." Executive Order 14401 (April 18, 2026) directs agencies to move faster but explicitly creates no enforceable right or benefit, names ibogaine and not psilocybin, and sets no deadlines. The Phase 3 psilocybin data everyone is citing comes from company press releases, not peer review, and shows a modest −3.6-point MADRS difference measured against a looser response threshold than antidepressant trials normally use. The $50M Texas ibogaine program traces substantially to a single open-label, uncontrolled, 30-person study. Meanwhile the only legal consumer pathways in the U.S. are Oregon's and Colorado's licensed programs, both of which will screen you out for lithium use, active psychosis, or self-harm ideation. When an outlet, a network, and a training business are the same ecosystem, check the evidence tier yourself before you check the vibe.
The short answer
The livestream is a fair hook for a real question: most outlets, networks, and "communities" covering psilocybin also sell something adjacent to it. That does not make the coverage wrong, but it means you should grade the evidence yourself — and right now the loudest claims rest on sponsor press releases, one uncontrolled 30-person study, and an executive order that changed nothing about federal law.
On September 23, 2026, the Psychedelics Today channel carried a livestream titled "PSA x PGN: Expanding the Scope of Community-Led Psychedelic Media," featuring Jack Gorsline of Psychedelic State(s) of America and Ashley Carmen, LMFT-S, of the Psychedelic Guide Network (https://www.youtube.com/watch?v=Y9egi8D5sfo).
Disclosure up front: we could not watch it. The video page returned an authentication error. We have the title, channel, publish date, and full description, and nothing else. So this is not a recap, and nothing below should be read as something the panelists said, implied, or would endorse. We are writing about the landscape the event sits in, because that landscape is verifiable and the panel's contents are not.
The question worth asking is simple. You are an adult trying to decide whether and how to engage with psilocybin. The information you use to make that call is produced by people. Who pays them, and does the science they are relaying support the confidence with which it gets relayed?
Who is in the room, and what they sell
Psychedelic State(s) of America is a journalism project with a fiscal sponsor and a public fund that has raised $1,825. The Psychedelic Guide Network sells ethics certification to facilitators. Psychedelics Today, the host, sells a 12-month training program and runs the media platform.
Psychedelic State(s) of America (PSA) describes itself at https://psychedelicamericas.org/ as "dedicated to empowering rigorously independent psychedelic news, commentary, analysis, and education." It lists partner outlets including DoubleBlind, Marijuana Moment, The Chronicles of Kykeon, and — as of the same September 23 date — the Psychedelic Guide Network, plus a syndication feed called PSA NewsWire. It launched as a 50-state journalism series in partnership with Lucid News, with contributors including Gorsline, Noah Daly, Dr. Alaina Jaster, and Joe Moore of Psychedelics Today (https://www.lucid.news/psychedelic-states-of-america-puts-a-spotlight-on-texas/).
Scale check. PSA's public media fund has raised $1,825 from 31 contributions over 55 weeks, with the Alternative Newsweekly Foundation as fiscal sponsor (https://fundrazr.com/PSANewsMedia). Stated uses include digital infrastructure, content production, an incubator, co-funding freelance wages, and pop-up events. That is not a criticism of anyone's effort. It is a number, and it tells you what independent psychedelic journalism is actually resourced at.
The Psychedelic Guide Network (PGN) is a practice community for facilitators founded by Ashley Carmen, LMFT, based in Austin, Texas. It meets twice monthly, sells InnerEthics® courses including a Level 1 certification alongside free tools, and runs application-reviewed "Wisdom Circles" (https://www.psychedelicguidenetwork.com/). It appears to be a for-profit business, not a nonprofit, and it does not provide clinical services.
Psychedelics Today, the host, calls itself "the planetary leader in psychedelic media, storytelling, and education" and sells a 12-month "Vital" training accreditation program plus a course catalog (https://www.psychedelicstoday.com/).
Here is what we will not do: imply any of the three takes money from drug companies, retreat operators, or training programs. We looked and found nothing — no Form 990, no budget disclosure, no funder list for any of them. Absence of evidence is not evidence, and we are not making the insinuation.
What is verifiable and fair to say: in this ecosystem, the outlet and the training business are frequently the same entity, and the media builds the audience that the certification is sold to. That is a structural fact about incentives, not an accusation about anyone's honesty. It is also exactly the fact that should make you grade sources rather than trust brands.
"Federal momentum" is not federal legality
Executive Order 14401 directs agencies to move faster on psychedelics but explicitly creates no enforceable right, names ibogaine rather than psilocybin, and sets no deadlines. Psilocybin remains Schedule I — Compass Pathways says so in its own SEC filing.
On April 18, 2026, President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness" (https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/). Read the actual text, because the coverage compresses it badly.
It directs the FDA Commissioner to issue National Priority Vouchers to psychedelic drugs holding Breakthrough Therapy designation. It directs FDA and DEA to establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act. It directs HHS to allocate at least $50 million from existing funds to partner with state governments. It directs the Attorney General to review any Schedule I product that has completed Phase 3 trials.
Now the parts that get left out. Ibogaine is named; psilocybin and MDMA are not. The order states it "is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party." It sets no explicit deadlines.
Six days later, on April 24, 2026, FDA reportedly issued National Priority Vouchers to Compass Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). We are hedging that one deliberately: we have it from trade coverage at The Microdose and Psychedelic Alpha, not from an FDA document we opened ourselves.
None of this makes anything legal for you. The clearest statement of that comes from the company with the most to gain. Compass Pathways' Form 10-Q for the quarter ended June 30, 2026 states plainly that psilocybin "must be rescheduled before commercializing COMP360 psilocybin in the U.S." — FDA approval alone is not enough (https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000058/cmps-20260630.htm). The same filing reports $433.3M in cash, sufficient into 2028, and a rolling NDA review underway. When a sponsor's risk-factors section is more cautious than the media around it, believe the sponsor.
Sort the evidence by tier before you sort it by headline
The Phase 3 psilocybin results are real randomized human data, but they come from press releases rather than peer review, and the effect sizes are modest. The ibogaine evidence driving a $50M state program is a single open-label study of 30 people with no control group.
Tier 1 — randomized controlled human trials (sponsor-reported, not yet peer-reviewed). COMP005 was randomized, double-blind, placebo-controlled, 258 participants with treatment-resistant depression across 32 U.S. sites. At Week 6 the 25 mg arm beat placebo by a mean of −3.6 MADRS points, p<0.001, with the data safety monitoring board reporting no new or unexpected safety findings and no evidence of a clinically meaningful suicidality imbalance between arms. COMP006, reported July 7, 2026, dosed 581 participants and found 39% of the 25 mg group achieved at least a 25% MADRS reduction at Week 6, maintained through Week 26; serious adverse events ran 6.3% in the 1 mg arm versus 5.7% in the 25 mg arm.
Four caveats the headlines skip:
- This is not peer-reviewed. Everything above comes from company press releases and an SEC filing. The 2022 Phase 2b was published in the New England Journal of Medicine; the Phase 3s, as of this writing, were not.
- The response bar is low. A 25% MADRS reduction is looser than the 50% cutoff conventional in antidepressant trials. In the Phase 2b, response was 37% at three weeks and 20% by twelve weeks on standard metrics (https://www.drugdiscoverytrends.com/first-phase-3-psilocybin-data-clears-the-bar-for-treatment-resistant-depression-but-how-high-was-the-bar/).
- The comparator in COMP006 was 1 mg psilocybin, not an inert placebo. That partly addresses blinding, which is the field's chronic problem — people usually know whether they got a psychedelic.
- No release we read quantifies functional unblinding or expectancy. That is the single biggest methodological question in this literature and we have no primary source characterizing it for these trials.
Tier 2 — open-label and uncontrolled. Cherian et al., "Magnesium–ibogaine therapy in veterans with traumatic brain injuries," *Nature Medicine*, January 2024 (https://www.nature.com/articles/s41591-023-02705-w). Thirty male U.S. Special Operations veterans. No control group. No randomization. Improvements were reported in disability, psychiatric symptoms, and cognition. Ibogaine is associated with fatal cardiac arrhythmia; magnesium co-administration is the proposed mitigation, not a proven one. We could not get past the paywall to read the limitations, funding, or conflict-of-interest statements.
That uncontrolled n=30 is a substantial part of the evidentiary basis for the largest publicly funded psychedelic research effort in U.S. history. Texas HB 3717 / SB 2308, signed June 2025, committed up to $50M contingent on a $50M private match to pursue FDA approval of an ibogaine drug. By March 2026, no drug company met the state's matching and revenue-share terms, and Texas announced it would run the trials itself through UTHealth Houston with UTMB Galveston. Drug policy researcher Katharine Neill Harris of Rice University's Baker Institute told the Texas Tribune that as SB 2308 is written, the state health agency "should not be able to release the $50 million in state funds to the consortium without the private match," and that the effort "will likely require much more than $100 million overall." State officials declined to explain why companies failed to qualify (https://www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/).
Tier 3 — observational aggregate data. Yu, Tafur, Moreno and Dahmer, *Frontiers in Psychiatry*, May 2026, analyzed Oregon Health Authority dashboard data for calendar 2025: 5,935 clients across 5,375 administration sessions. Behavioral adverse events ran 2.42 per 1,000 sessions; medical adverse events 2.79 per 1,000; seven severe reactions required hospital transport. The authors declare no funding and no commercial conflicts, and they are candid about limits — aggregate cross-sectional data, no validated outcome measures, voluntary reporting, missing demographics, repeat clients indistinguishable, no standardized causality assessment (https://pmc.ncbi.nlm.nih.gov/articles/PMC13224104/).
That is the most useful safety dataset in the piece, and it is still descriptive, not causal.
What is actually legal, and who gets screened out
Oregon and Colorado are the only U.S. states with a legal psilocybin pathway for adults, and neither is medical care. Both screen clients — Oregon disqualifies anyone who has taken lithium in the past 30 days or been diagnosed with active psychosis.
Oregon (ORS 475A / Measure 109). Clients must be 21 or older. Residency is not required. A preparation session with a licensed facilitator is mandatory before administration. Product may only be purchased at a licensed service center during a session and may not be taken off-site. A client is ineligible if they are experiencing ideation of harm to self or others, have taken lithium within 30 days, or have been diagnosed with active psychosis at any time. Facilitators may decline services for any reason (https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Access-Psilocybin-Services.aspx). See /legal-status/oregon.
Colorado (Natural Medicine Health Act). The Department of Revenue licenses healing centers, cultivation, manufacturing and testing; DORA licenses facilitators. The first healing center license was issued March 31, 2025, and the first regulated session took place June 6, 2025. See /legal-status/colorado and our side-by-side at /vs/oregon-vs-colorado-psilocybin-therapy.
No other state has a legal psilocybin pathway, and neither Oregon nor Colorado is medical care. Oregon frames it as facilitated services, not therapy, and facilitators are not required to be licensed clinicians.
On the lithium rule. The strongest available signal is anecdotal, and we will label it that way. Nayak, Gukasyan, Barrett, Erowid, Erowid and Griffiths, *Pharmacopsychiatry*, 2021, analyzed self-reported online accounts from Erowid, Shroomery and Reddit: 47% of 62 lithium-plus-psychedelic reports involved seizures, another 18% described bad trips, and 39% involved medical attention. Zero of 34 lamotrigine reports involved seizures. That is retrospective analysis of internet posts, not a controlled study — but it is consistent with why Oregon wrote a 30-day exclusion into the rules. More at /guides/psilocybin-and-lithium.
On antidepressants, both directions carry risk. Erritzoe and colleagues reported in the *Journal of Psychopharmacology* (2024) that in the psilocybin arm of their trial, patients who discontinued SSRIs or SNRIs to enter showed a reduced treatment effect on all outcome measures compared with patients who were unmedicated at entry. Blunting of acute effects in people taking serotonergic antidepressants is separately documented. So: blunting on one side, withdrawal and relapse risk on the other. This is a conversation with a prescriber, not a forum. See /guides/psilocybin-and-ssris, /guides/psilocybin-and-maois, and the overview at /guides/psilocybin-drug-interactions.
We do not publish dosing beyond /dosage and /guides/safe-trip, and nothing in the trial data above should be read across to anything you do outside a licensed program.
The cost of bad information is not theoretical
The FDA and CDC investigation into Diamond Shruumz products documented 180 illnesses across 34 states, 73 hospitalizations, and 3 potentially associated deaths — from products marketed to people who had no way to know what was in them.
When the information environment is thin, people buy from whoever is loudest.
FDA's investigation into Diamond Shruumz-brand chocolate bars, cones and gummies, last updated November 15, 2024, documented 180 illnesses across 34 states, 73 hospitalizations, and 3 potentially associated deaths. Agency lab testing found acetylpsilocin (4-AcO-DMT), psilocin, muscimol, ibotenic acid, pregabalin — a prescription drug — and kavalactones. FDA noted that muscimol "does not appear in all products and cannot explain all the symptoms reported" (https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-illnesses-diamond-shruumz-brand-chocolate-bars-cones-gummies-june-2024). Our page on that product line is at /brands/diamond-shruumz.
That is the failure mode. Not a bad take on a podcast — a shelf-stable product with an undisclosed prescription drug in it, bought by people who trusted packaging because nothing more trustworthy was available to them.
Good community media is a genuine counterweight to that. So is reading the primary document yourself, which takes about fifteen minutes and costs nothing.
PsyBear takeaways
Grade every claim by tier, read the sponsor's own risk disclosures, and remember that no executive order has made anything legal for you. The screening rules matter more to your safety than any headline about federal momentum.
1. Ask who pays, but do not answer the question with a guess. We could not find funding disclosures for PSA, PGN, or Psychedelics Today, so we are not asserting anything about their funders. What is verifiable is structural: in this space the media platform and the training business are often the same organization. Treat that as a reason to check sources, not as proof of bad faith.
2. "Federal momentum" and "federally legal" are different sentences. EO 14401 creates no enforceable right, names ibogaine rather than psilocybin, and sets no deadlines. Psilocybin is still Schedule I. Compass's own 10-Q says rescheduling must happen before commercialization.
3. Company press release ≠ peer review. The Phase 3 psilocybin results are randomized human data, which is the top tier of evidence — but they have not been through peer review, the effect sizes are modest (−3.6 MADRS points), and the reported response threshold is looser than antidepressant trials normally use.
4. An uncontrolled study of 30 people is not a treatment. The Cherian ibogaine paper is open-label with no control arm. It is hypothesis-generating. It is currently helping justify a program that Rice's Katharine Neill Harris says will likely need more than $100 million — and whose statutory funding condition has not visibly been met.
5. The screening rules are the harm reduction. Lithium in the past 30 days, any history of diagnosed active psychosis, current ideation of self-harm: Oregon excludes all three, and the lithium exclusion is backed by a seizure signal in self-reported data. If a program does not ask you these questions, that tells you something about the program. Start at /guides/safe-trip and /guides/trip-preparation.
6. Oregon's numbers are reassuring and limited. Roughly 5,900 clients in a year with seven hospital transports is a real-world safety picture worth having — and it is voluntary, aggregate, uncontrolled reporting with no validated outcome measures. The authors say so themselves.
Psilocybin remains a Schedule I substance under U.S. federal law. The only legal consumer pathways in the United States are Oregon's and Colorado's licensed programs, and neither is medical care. This article is commentary on public documents and published literature, not medical or legal advice. Psilocybin can interact dangerously with lithium and with serotonergic antidepressants, and is contraindicated for people with a history of psychosis — talk to a prescriber before changing any medication.
Key Takeaways
Psilocybin is still Schedule I federally — Compass Pathways says so in its own SEC filing, noting the drug "must be rescheduled before commercializing COMP360 psilocybin in the U.S." Executive Order 14401 (April 18, 2026) directs agencies to move faster but explicitly creates no enforceable right or benefit, names ibogaine and not psilocybin, and sets no deadlines. The Phase 3 psilocybin data everyone is citing comes from company press releases, not peer review, and shows a modest −3.6-point MADRS difference measured against a looser response threshold than antidepressant trials normally use. The $50M Texas ibogaine program traces substantially to a single open-label, uncontrolled, 30-person study. Meanwhile the only legal consumer pathways in the U.S. are Oregon's and Colorado's licensed programs, both of which will screen you out for lithium use, active psychosis, or self-harm ideation. When an outlet, a network, and a training business are the same ecosystem, check the evidence tier yourself before you check the vibe.
FAQ
- Did Executive Order 14401 make psychedelics legal?
- No. The April 18, 2026 order directs FDA, DEA and HHS to accelerate work on psychedelics, including at least $50 million allocated to partner with state governments, but it states explicitly that it does not create any right or benefit enforceable at law. It names ibogaine; it does not name psilocybin or MDMA, and it sets no deadlines. Psilocybin remains Schedule I under federal law.
- Have the Phase 3 psilocybin trial results been peer-reviewed?
- Not as of this writing. COMP005 and COMP006 results come from Compass Pathways press releases and the company's SEC filings, which is the sponsor's own framing. The earlier Phase 2b study was published in the New England Journal of Medicine in 2022, but the Phase 3 trials had not been published in a peer-reviewed journal when we checked.
- How strong is the evidence behind the Texas ibogaine program?
- Thinner than the funding suggests. A substantial part of the evidentiary basis is Cherian et al., Nature Medicine, January 2024 — an open-label, single-arm study of 30 male U.S. Special Operations veterans with no control group and no randomization. Texas committed up to $50 million contingent on a $50 million private match; by March 2026 no company had met the state's terms, and Texas said it would run trials itself through UTHealth Houston and UTMB Galveston.
- Can I use psilocybin legally if I take lithium?
- Not in Oregon's licensed program. Oregon rules make a client ineligible if they have taken lithium within the past 30 days, have been diagnosed with active psychosis at any time, or are experiencing ideation of harm to self or others. A 2021 Pharmacopsychiatry analysis of online experience reports found that 47% of 62 lithium-plus-psychedelic accounts involved seizures, versus zero of 34 lamotrigine accounts — anecdotal data, but consistent with the rule.
- How safe were Oregon's regulated psilocybin sessions in 2025?
- A Frontiers in Psychiatry analysis of Oregon Health Authority dashboard data for calendar 2025 found 5,935 clients across 5,375 administration sessions, with behavioral adverse events at 2.42 per 1,000 sessions, medical adverse events at 2.79 per 1,000, and seven severe reactions requiring hospital transport. The authors note the data is aggregate, voluntarily reported, and has no validated clinical outcome measures.
- What happened with Diamond Shruumz products?
- FDA's investigation, last updated November 15, 2024, documented 180 illnesses across 34 states, 73 hospitalizations, and 3 potentially associated deaths. Lab testing identified acetylpsilocin, psilocin, muscimol, ibotenic acid, the prescription drug pregabalin, and kavalactones, and FDA noted that muscimol could not explain all reported symptoms.